Stockscreener 앱 받기
10.44
3.06%
-0.33
전일 마감가:
$10.77
열려 있는:
$10.59
하루 거래량:
31,712
Relative Volume:
1.60
시가총액:
$738.92M
수익:
$370.44M
순이익/손실:
$12.19M
주가수익비율:
60.59
EPS:
0.1723
순현금흐름:
$50.74M
1주 성능:
-3.15%
1개월 성능:
-8.90%
6개월 성능:
-34.63%
1년 성능:
-29.08%
1일 변동 폭
$10.36
$10.64
1주일 범위
$10.36
$11.50
52주 변동 폭
$9.62
$21.34
Pharming Group Nv Adr Stock (PHAR) Company Profile
Compare PHAR vs VRTX, REGN, MRNA, ARGX, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
PHAR
Pharming Group Nv Adr
|
10.44 | 738.92M | 370.44M | 12.19M | 50.74M | 0.1723 |
VRTX
Vertex Pharmaceuticals Inc
|
522.38 | 132.40B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
796.02 | 81.95B | 14.92B | 4.42B | 3.79B | 41.04 |
MRNA
Moderna Inc
|
194.82 | 77.78B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
962.22 | 60.20B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
199.86 | 42.84B | 742.00K | -1.37B | -1.07B | -7.0731 |
Pharming Group Nv Adr Stock (PHAR) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-04-10 | 개시 | Canaccord Genuity | Buy |
| 2024-12-09 | 개시 | Jefferies | Buy |
Pharming Group Nv Adr 주식(PHAR)의 최신 뉴스
Canaccord reiterates Pharming stock rating on positive trial data - Investing.com
Pharming Group N.V. (PHAR) Stock Price, News, Quote & History - Yahoo! Finance Canada
Pharming Group N.V. stock gains on MAC Alpha Capital’s new USD 29.84 million stake - AD HOC NEWS
Pharming Group (NASDAQ: PHAR) Secures FDA Nod for Pediatric Use of Joenja in APDS Treatment - Kalkine Media
Zai Lab LimitedADR Peer Comparison – Compare with Others - Value Research
Pharming Group N.V. ADS each representing 10 (PHAR) Peer Comparison – Compare with Others - Value Research
XORTX Therapeutics Inc. (XRTX) Peer Comparison – Compare with Others - Value Research
Pharming Group N.V. Sponsored ADR (NASDAQ:PHAR) Short Interest Up 93.0% in July - MarketBeat
Pharming Group N.V. Sponsored ADR (NASDAQ:PHAR) Given Average Rating of "Hold" by Brokerages - MarketBeat
Pharming Group (NASDAQ:PHAR) Shares Gap DownShould You Sell? - MarketBeat
Pharming Group (NASDAQ:PHAR) Sees Unusually-High Trading VolumeTime to Buy? - MarketBeat
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation int - The National Law Review
Bronstein, Gewirtz & Grossman, LLC Is Investigating Pharming Grou - The National Law Review
Pharming Group (PHAR) Securities Investigation NoticeLevi & Korsinsky - Sahm
Pharming Group (NASDAQ:PHAR) Shares Gap UpTime to Buy? - MarketBeat
Q3 EPS Estimates for Pharming Group Lowered by HC Wainwright - MarketBeat
Pharming Group (NASDAQ:PHAR) Shares Gap Down Following Weak Earnings - MarketBeat
Meta Posts Mixed Q2 Results, Joins Coursera, Qualcomm And Other Big Stocks Moving Lower In Thursday’s Pre - Benzinga
Pharming Group N.V. Sponsored ADR (NASDAQ:PHAR) Short Interest Update - MarketBeat
Pharming Group NV Sponsored ADR Revenue Breakdown – DUS:PHG - TradingView
Pharming Group N.V. Sponsored ADR (NASDAQ:PHAR) Given Average Rating of "Hold" by Analysts - MarketBeat
Pharming Q1 2026 slides: Joenja growth offset by RUCONEST decline - Investing.com
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Aga - The National Law Review
Bronstein, Gewirtz & Grossman, LLC Encourages Pharming Group N.V - The National Law Review
A2QLQY Forecast — Price Target — Prediction for 2027 - TradingView
Pharming Group NV Sponsored ADR Actuals & Estimates (NASDAQ:PHAR) - TradingView
PHG Forecast — Price Target — Prediction for 2027 - TradingView
DBV Technologies (DBVT) soars 5.3%: Is further upside left in the stock? - MSN
DBV Technologies (DBVT) Soars 5.3%: Is Further Upside Left in the Stock? - Yahoo Finance
Pharming earnings in focus: Can rare disease growth offset Q1 dip? - Investing.com
Form 6K Pharming Group NV For: 28 May By Investing.com - Investing.com South Africa
PHARPharming Group NV ADR Stock Price and Quote - Finviz
Pharming Group gears up to report Q4 earnings: What's in the cards? - MSN
PHARM.AS Stock Price, Quote & Chart | PHARMING GROUP NV (AMS:PHARM) - ChartMill
Earnings call transcript: Pharming Group Q1 2026 revenue declines amid RUCONEST challenges By Investing.com - Investing.com South Africa
Earnings call transcript: Pharming Group Q1 2026 revenue declines amid RUCONEST challenges - Investing.com India
Pharming Group Q1 Earnings Call Highlights - Barchart.com
Earnings call transcript: Pharming Group Q1 2026 sees stock drop amid revenue decline - Investing.com
Snap, Whirlpool, Nerdwallet And Other Big Stocks Moving Lower In Thursday's Pre-Market Session - Benzinga
Pharming Group reports first quarter 2026 financial results; on track for Joenja® U.S. pediatric label expansion and launches in Japan and Europe in 2026 - GlobeNewswire Inc.
Pharming earnings in focus: Can rare disease growth offset Q1 dip? By Investing.com - Investing.com South Africa
Pharming Group N.V. Sponsored ADR (NASDAQ:PHAR) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
Pharming Group N.V. Sponsored ADR (NASDAQ:PHAR) Sees Significant Decline in Short Interest - MarketBeat
Pharming Group Nv Adr (PHAR) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.11%
1.87%
자본화:
|
볼륨(24시간):